-
May 24-27, 2022 International Society for Mechanical Circulatory Society (ISMCS) and European Mechanical Circulatory Society (EUMS) Joint Scientific Conference was successfully held in Hanover, Germany. Dr. Frank Lin, PhD, CTO of CH Biomedical, and Mr. Karl Nelson, Vice President of Clinical Operations were invited to attend the conference.
-
On November 25th 2021, the implantable CH-VAD® left ventricular assist system (CH-VAD® LVAS) of CH Biomedical was approved by the National Medical Products Administration (NMPA) for marketing (Registration No.: GXZZ 20213120987). CH-VAD LVAS was developed independently by CH Biomedical, it is the first Left Ventricular Assist Device (LVAD) with complete independent intellectual property rights approved by NMPA in China, and the first full magnetic levitation LVAD approved by NMPA.
-
In March 2021, the National Medical Products Administration (NMPA) appointed Jiangsu Medical Products Administration to carry out on-site inspection of Good Manufacturing Practice (GMP) quality management system of CH Biomedical. Inspection results showed that CH Biomedical is in compliance with GMP regulations without key nonconformities.
-
On January 5, 2020, "China’s First Mechanical Circulatory Support Conference" and "The First Preparatory Meeting of Mechanical Circulatory Support (MCS) Branch of Chinese Society of Biomedical Engineering (CSBE) " sponsored by National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital were held in Beijing.
-
In September 2019, the 26th Annual Meeting of the International Society Mechanical Circulatory Support (ISMCS) was held in Japan. CH Biomedical was invited to participate in this conference for the first time, indicating that the company has become one of the most recognized VAD enterprises today.
-
From 9th to 14th of June 2019, the Gordon Research Conference was held in Barcelona, Spain. The conference theme this year was on Mechanical Circulatory Support (MCS) and brought together world-renowned doctors, scholars, and researchers in MCS field. Dr. Chen, CEO of the company, and Dr. Lin, CTO were invited to attend the conference and delivered a plenary speech.
